American Century Companies Inc. Acquires 89,108 Shares of Inari Medical, Inc. (NASDAQ:NARI)

American Century Companies Inc. grew its stake in Inari Medical, Inc. (NASDAQ:NARI) by 9.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,068,487 shares of the company’s stock after acquiring an additional 89,108 shares during the period. American Century Companies Inc. owned 1.83% of Inari Medical worth $54,546,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of NARI. Vestal Point Capital LP boosted its position in Inari Medical by 342.9% during the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock valued at $63,922,000 after purchasing an additional 1,200,000 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Inari Medical in the 3rd quarter valued at approximately $1,397,000. Verition Fund Management LLC acquired a new stake in shares of Inari Medical in the 3rd quarter valued at approximately $1,235,000. Jane Street Group LLC grew its stake in shares of Inari Medical by 32.4% in the third quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock valued at $3,927,000 after buying an additional 23,286 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in Inari Medical during the third quarter worth $716,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on NARI shares. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Baird R W downgraded shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th. Piper Sandler boosted their price target on Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 7th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Oppenheimer started coverage on Inari Medical in a report on Tuesday, December 17th. They set an “outperform” rating and a $75.00 target price on the stock. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $68.00.

Insider Activity

In other news, Director William Hoffman sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at approximately $14,451,543.89. This trade represents a 45.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.60% of the stock is currently owned by company insiders.

Inari Medical Price Performance

Shares of NASDAQ NARI opened at $79.97 on Thursday. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. The stock’s fifty day moving average price is $79.85 and its two-hundred day moving average price is $60.95. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $79.99.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.